OMEGA-3-ACID ETHYL ESTERS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OMEGA-3-ACID ETHYL ESTERS (OMEGA-3-ACID ETHYL ESTERS).
Omega-3-acid ethyl esters decrease hepatic secretion of very-low-density lipoproteins (VLDL) and reduce triglycerides by inhibiting diacylglycerol acyltransferase and increasing beta-oxidation of fatty acids.
| Metabolism | Hydrolyzed by pancreatic lipases to free fatty acids; further metabolized via beta-oxidation. |
| Excretion | Primarily biliary/fecal: >90% of omega-3-acid ethyl esters are eliminated in feces as unchanged drug or metabolites. Renal excretion accounts for <5%. |
| Half-life | Terminal elimination half-life is approximately 8-10 hours for EPA and 12-24 hours for DHA. This supports twice-daily dosing and reflects slow turnover in plasma and tissues. |
| Protein binding | Highly protein-bound (>99%), primarily to albumin. Also binds to lipoproteins during transport. |
| Volume of Distribution | Approximately 0.1-0.3 L/kg, indicating limited distribution to total body water and preferential incorporation into cell membranes and adipose tissue. |
| Bioavailability | Bioavailability is approximately 20-30% under fasting conditions and up to 60-70% when taken with a meal rich in fat, due to enhanced absorption facilitated by dietary lipids. |
| Onset of Action | Oral: Reduction in triglycerides is observed after 2-4 weeks of consistent dosing; maximal effect may take 6-8 weeks. |
| Duration of Action | With chronic dosing, triglyceride lowering persists as long as therapy continues. Discontinuation leads to gradual return to baseline triglyceride levels within 4-8 weeks. |
4 g/day orally, divided once daily or in two divided doses of 2 g each, with meals.
| Dosage form | CAPSULE |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A or B). Not studied in severe hepatic impairment (Child-Pugh class C). |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended; use with caution due to potential age-related comorbidities and polypharmacy. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OMEGA-3-ACID ETHYL ESTERS (OMEGA-3-ACID ETHYL ESTERS).
| Breastfeeding | Excreted in human milk; M/P ratio not established. Use with caution, benefits likely outweigh risks. |
| Teratogenic Risk | No evidence of teratogenicity in animal studies; limited human data but considered low risk. No known structural anomalies. |
| Fetal Monitoring | Monitor triglyceride levels, bleeding time, and fetal growth if used in pregnancy. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to fish or omega-3-acid ethyl esters","Active pancreatitis (relative, if severe hypertriglyceridemia)","Concurrent use of anticoagulants/antiplatelets (caution, not absolute)"]
| Precautions | ["May increase LDL-C in some patients","Monitor for atrial fibrillation (especially with history of arrhythmia)","Increased risk of bleeding (inhibit platelet aggregation)","May prolong bleeding time"] |
Loading safety data…
| Fertility Effects | No adverse effects on fertility observed in animal studies; human data lacking. |